Connect Biopharma Holdings Ltd - ADR logo

CNTB

Connect Biopharma Holdings Ltd - ADR

$1.35

Key Ratios

Key ratios of the Connect Biopharma Holdings Ltd - ADR post its Q4 2021 earnings

Return on Assets (ROA)
-0.27
Return on Equity (ROE)
-3.68
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Connect Biopharma Holdings Ltd - ADR’s return on assets (ROA) stands at -0.27.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Connect Biopharma Holdings Ltd - ADR’s return on equity (ROE) stands at -3.68.

Dividend Per Share (DPS):

Connect Biopharma Holdings Ltd - ADR declared 0 dividend per share during the earnings announcement for Q4 2021.

Company Information

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

Organisation
Connect Biopharma Holdings Ltd - ADR
Headquarters
East R&D Building, Taicang, China, 215400
Employees
2021